Archive


Category: Verily

  • Alphabet’s Verily + L’Oréal Partner to Advance Precision Skin Health

    What You Should Know: – Today, Alphabet’s Verily, a world leader in personalized medicine, and L’Oréal, the world leader in beauty, joined forces to lead a new era of precision skin health. – The first-of-its-kind partnership in the beauty industry aims to break down barriers to dermatology care and bring new insights to dermatologists that […]

  • Smartphones could be used to detect depression, Verily finds

    A study published by Verily researchers showed that some smartphone metrics, such as sentiment in weekly voice diaries, matched up with the severity of users’ depression as determined by PHQ-9 scores. Even if these technologies could be used to track mental health, it’s not clear how they will fit into physician workflows or how comfortable […]

  • Mayo Clinic, Verily Partner to Develop Clinical Decision Support Solutions

    What You Should Know: – Today, Mayo Clinic and Verily, an Alphabet company announced a strategic two-year collaboration to develop clinical decision support solutions. This modular, evidence-based decision support solution, will provide contextualized and validated knowledge on disease management, care guidelines, and treatment to help clinicians make decisions. – The clinical decision support tool will […]

  • PharmaShots Weekly Snapshots (August 16 – 20, 2021)

    Janssen Presents Results of Rybrevant (amivantamab-vmjw) in P-I CHRYSALIS Study for Advanced NSCLC with METex14 Mutations at WCLC Published: Aug 20, 2021 | Tags: Astellas, FibroGen, Evrenzo, Roxadustat, EC, Approval, Symptomatic Anemia, Chronic Kidney Disease Astellas and FibroGen’s Evrenzo (roxadustat) Receive EC’s Approval for Symptomatic Anemia Associated with Chronic Kidney Disease Published: Aug 20, 2021 […]

  • Verily Acquires SignalPath to Expand its Clinical Research Capabilities

    Shots: The acquisition will bolster Verily’s clinical trial system and Baseline platform to improve the efficiency, costs in clinical trials & speed up it at research sites globally. It also collects patient data for site-based, hybrid, and decentralized clinical studies SignalPath’s platform leverages modern software architecture with a cloud-based platform to reduces fragmentation & advance […]

  • Colgate Taps Verily’s Baseline Platform for Oral Health Research

    What You Should Know: – Verily and Colgate, today announce a new oral health study as part of Verily’s ongoing Baseline Health Study that will aim to improve understanding of the connections between oral health and overall human health. The study will assess how oral health practices affect health more broadly. – The study’s goal […]

  • #Healthin2Point00, Episode 189 | DispatchHealth, TytoCare and Highmark Health

    Today on Health in 2 Point 00, we’re wishing Jess a happy belated birthday! On Episode 189, Jess asks me about DispatchHealth raising a massive $200 million Series D, bringing their total up to $403 million, providing in-home urgent care. TytoCare raises another $50 million for their Series D, bringing their total up to $155 […]

  • Highmark Health Taps Verily to Build Digital Health Tools for Living Health Model

    What You Should Know: – Highmark Health has engaged Verily to build out digital health tools for patients and analytics solutions for Highmark’s clinicians as part of its Living Health model. This marks the first collaboration of its kind for Verily, Google Cloud and a partner.   – Highmark Health is a Blue Cross Blue Shield health plan based in […]

  • Otsuka, Click trial digital depression therapy with Google

    Otsuka and Click Therapeutics are working with Verily, the healthcare subsidiary of Google owners Alphabet, on a fully remote clinical trial testing a digital therapy as an add-on in adults with severe depression. Otsuka is on a mission to develop digital technology to treat mental illness and broke new ground by marketed Abilify Mycite (aripiprazole) […]

  • Verily and Janssen Launch COVID-19 Immune Response Study

    What You Should Know: – Verily and Janssen launches COVID-19 Immune Response Study that aims to collect detailed information about how the coronavirus affects the immune system immediately after someone tests positive for COVID-19. Verily, an Alphabet company, is partnering with Janssen Research & Development LLC (Janssen) to launch a COVID-19 Immune Response Study as […]

  • Verily’s Onduo Virtual Care Solution Expands to Multi-Condition Platform

    What You Should Know: – Verily’s Onduo, known for its tech-based solution for virtual diabetes management, is launching a new multi-condition platform that matches the right care to the right consumer at the right time. The expanded virtual care platform is designed to support patients managing type 2 diabetes and hypertension, with plans for further expansion into mental […]

  • Top 5 Business Opportunities for Digital Health Companies in 2021. Where Is The Money?

    Ralf-Gordon Jahns, Managing Director of R2G For many companies, 2020 has been a devastating year due to the consequences of the COVID-19 pandemic. While the same can be said for the digital health sector, the pandemic has also paved a way for unexpected and extraordinary business opportunities in 2021. In 2020, Digital health start-ups and […]

  • Insights+: Key Deals of JP Morgan Healthcare Conference 2021

    This year J.P. Morgan 39th Annual Healthcare Conference was conducted virtually and we witnessed multiple announcements from numerous Biopharma companies An analysis of events and catalysts that were announced at the conference during these days are included in the report. Most of the deals occurred in the first two days of the conference Our PharmaShots […]

  • Google’s Verily eyes 2021 growth after £700m funding round

    Verily is planning “significant and focused growth” in 2021 after closing a $700 million funding round from investors including its parent company, and Google holding firm, Alphabet. The capital injection will support wide-ranging plans for the new year that include several life sciences programmes in surgery, pathology and immunology, which would add to the digital […]

  • How Verily plans to use $700M in new funding

    Alphabet and other investors poured $700 million in funding into Verily last week. The company, which is Alphabet’s life sciences subsidiary, plans to pour some of the funds into supporting Covid-19 vaccine studies and programs for businesses.

  • Verily Nabs $700M to Expand Baseline, Verily Health Platforms

    What You Should Know: – Verily, a subsidiary of Alphabet focused on life sciences and healthcare announced it has raised $700M from current investors, including Alphabet, Silver Lake, Temasek, Ontario Teachers’ Pension Plan and others. – The company plans to use the capital to support rapid expansion of some of Verily’s leading commercial businesses including […]

  • Verily co-founder launches virtual specialty care startup

    Tom Stanis, Verily’s co-founder and former head of software, left the Alphabet subsidiary in February to found a new healthcare startup. Called Story Health, his new startup is focused on providing care in the gaps between specialty visits.

  • Lessons learned from Verily’s Covid-19 testing efforts

    Google’s sister company launched a program in California and other states to help route patients to nearby coronavirus testing. Dr. Vivian Lee, president of health platforms for Verily, shared lessons learned from that effort and Verily’s work with schools and businesses.

  • Verily launches stop-loss health insurance subsidiary

    Alphabet’s healthcare subsidiary, Verily, will partner with Swiss Re Corporate Solutions to create a new stop-loss insurance company. The new entity, called Coefficient, will use data analytics to help self-funded companies manage unexpected areas of cost.

  • Verily Forms New Subsidiary Focused on Employer Stop-Loss Through Precision Risk

    What You Should Know: – Alphabet’s Verily has established a new subsidiary, Coefficient, with a mission to create value by combining innovative health technology solutions with new insurance and payment models. Verily is the majority shareholder and Swiss Re Corporate Solutions, an established player in the employer stop-loss market, has a minority stake in the […]

  • PharmaShots Weekly Snapshot (Aug 10 – 14, 2020)

    1. Roche’s Evrysdi (risdiplam) Receives the US FDA’s Approval for SMA in Adults and Children Published: Aug 10, 2020 | Tags: Roche, Evrysdi, risdiplam, Receives, US, FDA, Approval, SMA, Adults, Children 2.  The US FDA Approves Guardant360 CDx as the First Liquid Biopsy NGS Assay to Identify EGFR Mutations in Non-Small Cell Lung Cancer Published: Aug 07, […]

  • Alphabet’s Verily Establishes CLIA-Certified Lab Focusing on COVID-19 Testing

    Shots: Verily has expedite the COVID-19 testing with a new lab-based at South San Francisco. The lab will use the technology from Thermo Fisher Scientific’s‎ TaqPath test kit that has received the US FDA’s EUA to test COVID-19 Verily has submitted a EUA for an adaptation of the TaqPath test to use in testing pooled […]